Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Heise

Showing results (111-120 of 150) with videos related to

Pageof 15
Sort By:
Diabetologia|December 26, 2015
Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetesElza Muscelli, Brenno Astiarraga, Elisabetta Barsotti, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 22, 2024
Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 DiabetesTim Heise, Grit Andersen, Edward J Pratt, et al.
Plos One|March 27, 2012
Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial)Alexander Strom, Hubert Kolb, Stephan Martin, et al.
Diabetes, Obesity & Metabolism|August 7, 2024
ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetesGrit Andersen, Rosy Eloy, Tim Heise, et al.
Plos One|April 3, 2018
Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in individuals with type 1 diabetesOthmar Moser, Max L Eckstein, Olivia McCarthy, et al.
Diabetes, Obesity & Metabolism|September 22, 2023
Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulinsWei Chen, Jia Lu, Leona Plum-Mörschel, et al.
Diabetes, Obesity & Metabolism|January 12, 2023
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetesGrit Andersen, Rosy Eloy, Susanne Famulla, et al.
Diabetes, Obesity & Metabolism|January 6, 2025
Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysisKieren J Mather, Andrea Mari, Govinda Weerakkody, et al.
Diabetes, Obesity & Metabolism|March 5, 2019
Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetesGrégory Meiffren, Theresa Herbrand, Ernestos Anastassiadis, et al.
Diabetes, Obesity & Metabolism|October 13, 2018
Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitusAhmed Al-Qaissi, Maria Papageorgiou, Zeeshan Javed, et al.
Pageof 15

Showing results (111-120 of 150) with videos related to

Sort By:
Pageof 15
Diabetologia|December 26, 2015
Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetesElza Muscelli, Brenno Astiarraga, Elisabetta Barsotti, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 22, 2024
Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 DiabetesTim Heise, Grit Andersen, Edward J Pratt, et al.
Plos One|March 27, 2012
Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial)Alexander Strom, Hubert Kolb, Stephan Martin, et al.
Diabetes, Obesity & Metabolism|August 7, 2024
ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetesGrit Andersen, Rosy Eloy, Tim Heise, et al.
Plos One|April 3, 2018
Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in individuals with type 1 diabetesOthmar Moser, Max L Eckstein, Olivia McCarthy, et al.
Diabetes, Obesity & Metabolism|September 22, 2023
Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulinsWei Chen, Jia Lu, Leona Plum-Mörschel, et al.
Diabetes, Obesity & Metabolism|January 12, 2023
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetesGrit Andersen, Rosy Eloy, Susanne Famulla, et al.
Diabetes, Obesity & Metabolism|January 6, 2025
Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysisKieren J Mather, Andrea Mari, Govinda Weerakkody, et al.
Diabetes, Obesity & Metabolism|March 5, 2019
Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetesGrégory Meiffren, Theresa Herbrand, Ernestos Anastassiadis, et al.
Diabetes, Obesity & Metabolism|October 13, 2018
Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitusAhmed Al-Qaissi, Maria Papageorgiou, Zeeshan Javed, et al.
Pageof 15